48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

Foundation for Liver Research138 enrolled

Overview

The purpose of this study is to investigate whether in patients with chronic HBeAg-negative hepatitis B, PEG-IFN-ribavirin combination therapy for 1 year leads to enhanced response (HBV DNA \<10E4 copies/ml and normal ALT 24 weeks after treatment discontinuation) in comparison with pegylated interferon (PEG-IFN) monotherapy.

Despite the introduction of newer drugs for the treatment of chronic hepatitis B, there is still no optimal treatment. Pegylated interferon alfa has proven sustained efficacy in approximately 30-40% of patients with HBeAg-positive or HBeAg-negative chronic hepatitis B. It is likely that combination therapy of pegylated interferon alfa with ribavirin in chronic hepatitis B is more effective than pegylated interferon alfa monotherapy. In chronic hepatitis C, adding ribavirin to pegylated interferon therapy doubled the sustained response rate (29% vs. 56%) and has become the standard option of treatment. To investigate the effect of the treatment with pegylated interferon and ribavirin on the amount of inflammation and fibrosis in the liver, a liver biopsy will be performed within one year prior to screening and at the end of follow-up. When patients with chronic hepatitis B are treated outside any study with pegylated interferon, they visit the outpatient clinic approximately every month for blood samples. So in this study the amount of blood samples taken from every patient is not increased as compared with treatment outside a study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

138

Conditions

Hepatitis B

Interventions

RibavirinDRUG

1200 mg a day, 48 weeks

Peginterferon alpha 2aDRUG

180 µg per week, 48 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic hepatitis B * Biopsy performed within one year prior to screening or during screening * ALT \> 1.5 x ULN * HBeAg negative, anti-HBeAg positive * HBV DNA \> 10E5 copies/ml * Age 18-70 years * Written informed consent * Hepatic imaging without evidence of HCC * All fertile males and females must be using two forms of effective contraception Exclusion Criteria: * Antiviral therapy against HBV within the previous 6 months; treatment with any investigational drug within 30 days of entry to this protocol * Severe hepatitis activity as documented by ALT \> 10 x ULN * Advanced liver disease * Pre-existent leucopenia or thrombopenia * Co-infection with HCV,HDV or HIV * Other acquired or inherited causes of liver disease * Alpha fetoprotein \> 50 ng/ml. * Evidence of severe renal disease * Hyper- or hypothyroidism * Significant cardiovascular or pulmonary dysfunction, malignancy,immunodeficiency syndromes * Immune suppressive treatment within the previous 6 months * Contra-indications for alpha-interferon therapy * Pregnancy, breast-feeding * Any medical condition requiring chronic systemic administration of steroids * Substance alcohol or drug abuse * Subjects with clinically significant retinal abnormalities * Subjects with clinically significant hearing abnormalities * Hemoglobinopathies * Subjects with known hypersensitivity to ribavirin

Locations (1)

Erasmus MC department hepatology

Rotterdam, Netherlands

Outcomes

Primary Outcomes

The combined presence of HBV DNA level < 10E4 copies/ml and ALT normalization at the end of follow-up

Time frame: may 2008

Secondary Outcomes

ALT normalization

Time frame: May 2008

HBV DNA negativity(undetectable by Taqman PCR)

Time frame: May 2008

HBsAg loss from serum

Time frame: May 2008

Improvement liver histology

Time frame: May 2008

Combined virological, biochemical and histological response

Time frame: May 2008

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.